ERX1000
Phase 2Small molecule
ERX1000 is one of 36 small molecule programs targeting Obesity. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1Actemra
RochePreclinical
Avapro
SanofiPreclinical
Adenocard
AstellasPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Cetrotide
EMD SeronoPreclinical
ERX1000
EERX Pharmaceuticals
Phase 2
Advil
KKenvue Brands
Preclinical
EGRIFTA WR
TTheratechnologies
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ERX1000. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EERX Pharmaceuticals